Intensity moves to resume INVINCIBLE-3 sites, restarts TNBC treatment, reports $9.5M cash
The company targets a limited U.S. site restart for its Phase 3 sarcoma trial by Q3 2026 while presurgical TNBC dosing has resumed under a revised protocol.
SEC filing